Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma

Farid, Suzanne S.; Washbrook, John; Titchener‐Hooker, Nigel J.

doi:10.1016/j.compchemeng.2006.10.020

Cited by 45 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inc., San Jose, CA), capable of modeling the operational, economic, environmental, and risk features associated with biopharmaceutical manufacture. The tool was based on a hierarchical data structure outlined by previous UCL work (Farid et al, 2000, 2005, 2007; Stonier et al, 2009) that breaks down a manufacturing campaign into individual unit operation subtasks at the lowest level. However, the tool required specification of a new level in the form of sub‐batches so as to capture the fact that a perfusion reactor generates multiple sub‐batches in the form of daily perfusate harvests, which are then subsequently pooled into larger sub‐batches prior to further purification.…”

Section: Methodsmentioning

confidence: 99%

The prevalence of psoriatic arthritis in people with psoriasis

Ibrahim¹,

Waxman²,

Helliwell³

2009

Arthritis & Rheumatism

215

115

View full text Add to dashboard Cite

Objective. To determine the prevalence of psoriatic arthritis (PsA) using the ClASsification criteria for Psoriatic ARthritis (CASPAR) for classification. Methods. People with psoriasis were identified from the computerized morbidity indices of 2 large UK general practices, total population 22,500. Questionnaires were mailed to all 633 patients thus identified. Of the respondents, a 50% sample was assessed clinically and a proportion had blood samples and radiographs taken. Patients labeled as having psoriasis were also cross-referenced with a local secondary care morbidity index for PsA and rheumatoid arthritis. Figures for the prevalence of PsA were estimated from these data. Results. One hundred sixty-eight questionnaires were returned (response rate 27%) and 93 people (55% of questionnaire respondents) were examined. Of these 93 people, 12 (4 of whom were cross-referenced to the hospital database) were thought to have PsA clinically, all fulfilling the CASPAR criteria for PsA. Six of the 93 examined patients did not have psoriasis or a family history of psoriasis and had no historical features or clinical signs of psoriasis on interview and examination. Extrapolating from the data of those people actually examined, the estimated (corrected) prevalence was 13.8% (95% confidence interval 7.1-24.1%). Conclusion. The estimated prevalence of PsA in this population, using the CASPAR criteria, was 13.8%. Misclassification of psoriasis and arthritis, and response bias, indicate that this is probably an overestimate.

show abstract

Section: Methodsmentioning

confidence: 99%

The prevalence of psoriatic arthritis in people with psoriasis

Ibrahim¹,

Waxman²,

Helliwell³

2009

Arthritis & Rheumatism

215

115

View full text Add to dashboard Cite

show abstract

“…A range of software tools have been developed to perform bioprocess modelling and economical analysis . These include BioSolve (Biopharm Services, Chesham, Buckinghamshire, UK), SimBioPharma (University College London, London, UK), SuperPro Designer (Intelligen, Scotch Plains, NJ), Aspen Batch Plus (Aspen Technology, Cambridge, MA), etc.…”

Section: Introductionmentioning

confidence: 99%

“…A range of software tools have been developed to perform bioprocess modelling and economical analysis. 28,29 These include BioSolve (Biopharm Services, Chesham, Buckinghamshire, UK), SimBioPharma (University College London, London, UK), SuperPro Designer (Intelligen, Scotch Plains, NJ), Aspen Batch Plus (Aspen Technology, Cambridge, MA), etc. BioSolve is an Excel-based software, that takes into account direct and indirect costs and contains an extensive library for equipment and materials with costs collected directly from suppliers.…”

Section: Introductionmentioning

confidence: 99%

Economic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle)

Torres‐Acosta

Aguilar‐Yáñez

Rito‐Palomares

et al. 2015

Biotechnol Progress

Self Cite

View full text Add to dashboard Cite

Uricase is the enzyme responsible for the breakdown of uric acid, the key molecule leading to gout in humans, into allantoin, but it is absent in humans. It has been produced as a PEGylated pharmaceutical where the purification is performed through three sequential chromatographic columns. More recently an aqueous two‐phase system (ATPS) was reported that could recover Uricase with high yield and purity. Although the use of ATPS can decrease cost and time, it also generates a large amount of waste. The ability, therefore, to recycle key components of ATPS is of interest. Economic modelling is a powerful tool that allows the bioprocess engineer to compare possible outcomes and find areas where further research or optimization might be required without recourse to extensive experiments and time. This research provides an economic analysis using the commercial software BioSolve of the strategies for Uricase production: chromatographic and ATPS, and includes a third bioprocess that uses material recycling. The key parameters that affect the process the most were located via a sensitivity analysis and evaluated with a Monte Carlo analysis. Results show that ATPS is far less expensive than chromatography, but that there is an area where the cost of production of both bioprocesses overlap. Furthermore, recycling does not impact the cost of production. This study serves to provide a framework for the economic analysis of Uricase production using alternative techniques. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 32:126–133, 2016

show abstract

“…Farid et al [7], however, point out that the financial squeeze on biopharmaceutical companies has triggered renewed interest in manufacturing and its contribution to business performance. Hence, emphasis on estimating and improving the manufacturing costs in the biotech-industry is growing.…”

Section: Introductionmentioning

confidence: 99%

Remote engineering for a cheese whey biorefinery: an Internet-based application for process design, economic analysis, monitoring, and control of multiple plant sites

Pinto

Giordano

2008

Bioprocess Biosyst Eng

View full text Add to dashboard Cite

The proteolysis of cheese whey with the aid of immobilized enzymes is an attractive alternative for this by-product of the dairy industry. Among some possible applications for whey protein hydrolysates, one may cite their use as protein source for individuals with reduced capacity of digestion, or with genetic metabolic disorders (phenylketonuria patients, for instance). The multipurpose plant that processes whey is named here as a cheese whey biorefinery. This work presents the remote control and monitoring of the whey biorefineries using the Internet. In an integrated environment, the web application also enables simulation and economic analyses of the process. This technology might allow small companies to access a remote "engineering centre", with know-how on plant design and advanced control techniques. The idea can also be extended to large dairy companies, providing the remote control of geographically spread sites of production.

show abstract

Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma

Cited by 45 publications

References 28 publications

The prevalence of psoriatic arthritis in people with psoriasis

The prevalence of psoriatic arthritis in people with psoriasis

Economic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle)

Remote engineering for a cheese whey biorefinery: an Internet-based application for process design, economic analysis, monitoring, and control of multiple plant sites

Contact Info

Product

Resources

About